Navigation Links
Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company
Date:8/17/2011

fatal disease affecting about 30% -50% of patients who undergo bone marrow transplantation. GVHD currently has no effective treatment and the size of this market opportunity is estimated at $300 million annually. The company's success in GVHD is expected to open additional markets in autoimmune and inflammatory diseases, a field which is the third sector in scope in the pharmaceutical world (after cancer and heart disease) and is estimated at billions of dollars.

The company is developing a drug treatment based on inducing immune tolerance by injecting the patient's autologous cells (or donor cells in the case of GVHD) in the early stages of programmed death. The technology is based on years of research by Prof. Dror Mevorach from the Hadassah Medical Center - a world renowned expert in the field of programmed cell death.

About Hadasit Bio-Holdings

Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center.  The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.  

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. The portfolio companies develop drugs with blockbuster potential (markets that are worth over a billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

For more information please visit:

SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... LAVAL, Quebec , November 21, 2014 ... Martensen wechselt als Chief Commercial Officer zu KLOX ... zum SVP der Unternehmensentwicklung und Chief Financial Officer bestellt ... in Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems ... Technologies Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, ...
(Date:11/21/2014)... November 20, 2014 Author Matthew J. ... to the Other Side” published as a tribute ... in the “Fiction: Short Story” category of the ... President and CEO of USA Book News, said this ... independent publishers, including Simon & Schuster, Penguin, John Wiley ...
(Date:11/21/2014)... Why did Stephen Hawking become so ... instantly recognizable? Why have they become icons to rival ... Hilton Ratcliffe seeks out the answers to those questions, ... do with science. In " Stephen Hawking Smoked My ... 2014), Ratcliffe puts it plainly: , “It is ...
(Date:11/21/2014)... NEW YORK and SAN DIEGO ... CYTX ), today announced that President and CEO Marc Hedrick ... 2014. DATE:   Thursday, December 4, 2014 ... LINK:     Click here or paste this URL into ... is recommended that investors pre-register to save time and receive ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... Danaher Corporation (NYSE: DHR ) announced today ... approximately 97% of the currently issued shares of Genetix Group ... dated December 18, 2009. , Danaher intends to acquire any ... acquisition provisions of the applicable UK companies legislation. , ...
... , TSX Exchange Symbol: RVX , Also ... SAN FRANCISCO, CA and CALGARY, Jan. 11 /PRNewswire-FirstCall/ - ... that Donald J. McCaffrey will be presenting at the ... at the Marines, Memorial Club and Hotel in San ...
... , BOSTON, Jan. 11 PAREXEL International ... expectations for the second quarter of Fiscal Year 2010 ended ... ending June 30, 2010. The Company,s updated financial guidance ... business wins and cancellations, revised expectations for the amount and ...
Cached Biology Technology:Danaher Completes Offer for Genetix Group plc 2Resverlogix Presenting at Biotech Showcase 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... management needs to take a longer look into the past ... involving Simon Fraser University researchers. That is ... online in Proceedings of the National Academy of Sciences ... Lertzman, and scientists in Ontario, Alberta and the United States ...
... Wintersteen, dean of Iowa State University,s College of Agriculture ... of public-private partnerships in strengthening global food security during ... Advancement of Science in Chicago., , During her talk, ... sustainable agriculture and food security, Wintersteen stressed the importance ...
... for life on earth, is also its least explored ... into the ocean,s deep regions, exploiting the deep,s resources ... services for the planet at risk. Lisa Levin, ... UC San Diego, believes the vital functions provided by ...
Cached Biology News:Ancient herring catch nets fisheries weakness 2Iowa State University's Wintersteen talks partnerships at national science meeting 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 3
... number is a new product number, ... number. If showing no availability yet, ... number (Z71,487-9) or contact customer service ... neck 100 mm, No. of sidearm ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Bio-Beads S-X media are ... for size exclusion chromatography of ... that require organic eluents. The ... toluene, xylene, carbon tetrachloride, dimethylformamide, ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: